Megazon

Quetiapine, the active ingredient in Megazon, is a atypical antipsychotic presented as a tablet for oral use. It treats schizophrenia, bipolar disorder and is used as adjunctive therapy for major depressive disorder in adults, helping to manage psychotic symptoms and mood instability.

GNH USA supplies Megazon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across EU and global markets. The company leverages a robust distribution network to provide reliable, on‑time delivery and supports customers with technical and regulatory assistance.

Quetiapine is an atypical antipsychotic that acts on multiple neurotransmitter pathways in psychiatric disorders.

- Schizophrenia: reduces hallucinations, delusions and thought disorder. - Bipolar disorder: stabilizes mood and prevents manic or depressive episodes. - Major depressive disorder (adjunctive): enhances antidepressant response when added to standard therapy.

Quetiapine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness or sedation - Dry mouth - Constipation - Weight gain

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Agranulocytosis - Severe orthostatic hypotension

When prescribing quetiapine, clinicians should consider several safety precautions.

- Monitor metabolic parameters: check weight, glucose and lipid levels regularly. - Assess for orthostatic hypotension: measure blood pressure when standing, especially at treatment initiation. - Use caution in elderly patients: increased sensitivity to sedation and falls. - Avoid abrupt discontinuation: taper dose to reduce risk of withdrawal symptoms. - Review concomitant CNS depressants: adjust dosing to prevent excessive sedation. - Store at room temperature: keep in the original container, protect from moisture and light.

Quetiapine interacts with several medicines that can alter its plasma concentration or increase adverse effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise quetiapine levels and risk toxicity. - CNS depressants (alcohol, benzodiazepines, opioids): can cause additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampin, carbamazepine, phenytoin): may lower quetiapine concentrations, reducing efficacy. - Antihypertensive agents: quetiapine may enhance orthostatic hypotension, requiring blood pressure monitoring. - Anticholinergic drugs: combined use may increase anticholinergic burden and cognitive effects.